Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 428

1.

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

Gadgeel S, Rodríguez-Abreu D, Speranza G, Esteban E, Felip E, Dómine M, Hui R, Hochmair MJ, Clingan P, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Garon EB, Novello S, Rubio-Viqueira B, Boyer M, Kurata T, Gray JE, Yang J, Bas T, Pietanza MC, Garassino MC.

J Clin Oncol. 2020 Mar 9:JCO1903136. doi: 10.1200/JCO.19.03136. [Epub ahead of print]

PMID:
32150489
2.

Locally Advanced, Unresectable Non-Small Cell Lung Cancer.

Puri S, Saltos A, Perez B, Le X, Gray JE.

Curr Oncol Rep. 2020 Mar 5;22(4):31. doi: 10.1007/s11912-020-0882-3. Review.

PMID:
32140986
3.

Pores for Thought: Can Genetic Manipulation of Stomatal Density Protect Future Rice Yields?

Buckley CR, Caine RS, Gray JE.

Front Plant Sci. 2020 Feb 11;10:1783. doi: 10.3389/fpls.2019.01783. eCollection 2019. Review.

4.

CrRLK1L receptor-like kinases HERK1 and ANJEA are female determinants of pollen tube reception.

Galindo-Trigo S, Blanco-Touriñán N, DeFalco TA, Wells ES, Gray JE, Zipfel C, Smith LM.

EMBO Rep. 2020 Feb 5;21(2):e48466. doi: 10.15252/embr.201948466. Epub 2019 Dec 23.

PMID:
31867824
5.

Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer.

Leighl NB, Karaseva N, Nakagawa K, Cho BC, Gray JE, Hovey T, Walding A, Rydén A, Novello S.

Eur J Cancer. 2020 Jan;125:49-57. doi: 10.1016/j.ejca.2019.11.006. Epub 2019 Dec 12.

6.

A Molecular Epidemiological Analysis Of Programmed Cell Death Ligand-1 (PD-L1) Protein Expression, Mutations And Survival In Non-Small Cell Lung Cancer.

Schabath MB, Dalvi TB, Dai HA, Crim AL, Midha A, Shire N, Gimbrone NT, Walker J, Greenawalt DM, Lawrence D, Rigas JR, Brody R, Potter D, Kumar NS, Huntsman SA, Gray JE.

Cancer Manag Res. 2019 Nov 7;11:9469-9481. doi: 10.2147/CMAR.S218635. eCollection 2019.

7.

Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy.

Mu W, Tunali I, Gray JE, Qi J, Schabath MB, Gillies RJ.

Eur J Nucl Med Mol Imaging. 2020 May;47(5):1168-1182. doi: 10.1007/s00259-019-04625-9. Epub 2019 Dec 5.

PMID:
31807885
8.

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.

Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators.

N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.

PMID:
31751012
9.

A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.

Boyle TA, Quinn GP, Schabath MB, Muñoz-Antonia T, Saller JJ, Duarte LF, Hair LS, Teer JK, Chiang DY, Leary R, Wong CC, Savchenko A, Singh AP, Charette L, Mendell K, Gorgun G, Antonia SJ, Chiappori AA, Creelan BC, Gray JE, Haura EB.

Cancer Med. 2020 Jan;9(1):225-237. doi: 10.1002/cam4.2670. Epub 2019 Nov 20.

10.

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.

Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, Planchard D, Paz-Ares L, Faivre-Finn C, Vansteenkiste JF, Spigel DR, Wadsworth C, Taboada M, Dennis PA, Özgüroğlu M, Antonia SJ.

J Thorac Oncol. 2020 Feb;15(2):288-293. doi: 10.1016/j.jtho.2019.10.002. Epub 2019 Oct 14.

11.

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.

Hui R, Özgüroğlu M, Villegas A, Daniel D, Vicente D, Murakami S, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Gray JE, Rydén A, Viviers L, Poole L, Zhang Y, Dennis PA, Antonia SJ.

Lancet Oncol. 2019 Dec;20(12):1670-1680. doi: 10.1016/S1470-2045(19)30519-4. Epub 2019 Oct 7.

PMID:
31601496
12.

Author Correction: Rice plants overexpressing OsEPF1 show reduced stomatal density and increased root cortical aerenchyma formation.

Mohammed U, Caine RS, Atkinson JA, Harrison EL, Wells D, Chater CC, Gray JE, Swarup R, Murchie EH.

Sci Rep. 2019 Oct 10;9(1):14827. doi: 10.1038/s41598-019-51402-7.

13.

The influence of stomatal morphology and distribution on photosynthetic gas exchange.

Harrison EL, Arce Cubas L, Gray JE, Hepworth C.

Plant J. 2020 Feb;101(4):768-779. doi: 10.1111/tpj.14560. Epub 2019 Nov 10.

14.

Application of Bayesian predictive probability for interim futility analysis in single-arm phase II trial.

Chen DT, Schell MJ, Fulp WJ, Pettersson F, Kim S, Gray JE, Haura EB.

Transl Cancer Res. 2019 Jul;8(Suppl 4):S404-S420. doi: 10.21037/tcr.2019.05.17.

15.

Patient preferences of chemotherapy treatment options and tolerance of chemotherapy side effects in advanced stage lung cancer.

Islam KM, Anggondowati T, Deviany PE, Ryan JE, Fetrick A, Bagenda D, Copur MS, Tolentino A, Vaziri I, McKean HA, Dunder S, Gray JE, Huang C, Ganti AK.

BMC Cancer. 2019 Aug 27;19(1):835. doi: 10.1186/s12885-019-6054-x.

16.

Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste J, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, Li-Sucholeiki X, Lentrichia B, Dearden S, Jenkins S, Saggese M, Rukazenkov Y, Ramalingam SS.

Clin Cancer Res. 2019 Nov 15;25(22):6644-6652. doi: 10.1158/1078-0432.CCR-19-1126. Epub 2019 Aug 22.

PMID:
31439584
17.

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.

Gray JE, Saltos A, Tanvetyanon T, Haura EB, Creelan B, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, Chen Z, Tchekmedyian N, Goas K, Thapa R, Boyle TA, Chen DT, Beg AA.

Clin Cancer Res. 2019 Nov 15;25(22):6623-6632. doi: 10.1158/1078-0432.CCR-19-1305. Epub 2019 Aug 13.

PMID:
31409616
18.

Patient-Defined Treatment Success: Perspectives of Patients With Advanced-Stage Lung Cancer.

Islam KM, Deviany PE, Anggondowati T, Ryan JE, Fetrick A, Bagenda D, Copur MS, Tolentino A, Vaziri I, McKean HA, Dunder S, Gray JE, Huang CMD, Ganti AK.

J Oncol Pract. 2019 Sep;15(9):e758-e768. doi: 10.1200/JOP.18.00734. Epub 2019 Jul 19.

PMID:
31322990
19.

Mesophyll porosity is modulated by the presence of functional stomata.

Lundgren MR, Mathers A, Baillie AL, Dunn J, Wilson MJ, Hunt L, Pajor R, Fradera-Soler M, Rolfe S, Osborne CP, Sturrock CJ, Gray JE, Mooney SJ, Fleming AJ.

Nat Commun. 2019 Jun 27;10(1):2825. doi: 10.1038/s41467-019-10826-5.

20.

Reduced stomatal density in bread wheat leads to increased water-use efficiency.

Dunn J, Hunt L, Afsharinafar M, Meselmani MA, Mitchell A, Howells R, Wallington E, Fleming AJ, Gray JE.

J Exp Bot. 2019 Sep 24;70(18):4737-4748. doi: 10.1093/jxb/erz248.

21.

Bacterial infection systemically suppresses stomatal density.

Dutton C, Hõrak H, Hepworth C, Mitchell A, Ton J, Hunt L, Gray JE.

Plant Cell Environ. 2019 Aug;42(8):2411-2421. doi: 10.1111/pce.13570. Epub 2019 Jun 10.

22.

Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.

Sequist LV, Gray JE, Harb WA, Lopez-Chavez A, Doebele RC, Modiano MR, Jackman DM, Baggstrom MQ, Atmaca A, Felip E, Provencio M, Cobo M, Adiwijaya B, Kuesters G, Kamoun WS, Andreas K, Pipas JM, Santillana S, Cho BC, Park K, Shepherd FA.

Oncologist. 2019 Aug;24(8):1095-1102. doi: 10.1634/theoncologist.2018-0695. Epub 2019 Apr 11.

23.

Rice plants overexpressing OsEPF1 show reduced stomatal density and increased root cortical aerenchyma formation.

Mohammed U, Caine RS, Atkinson JA, Harrison EL, Wells D, Chater CC, Gray JE, Swarup R, Murchie EH.

Sci Rep. 2019 Apr 3;9(1):5584. doi: 10.1038/s41598-019-41922-7. Erratum in: Sci Rep. 2019 Oct 10;9(1):14827.

24.

Loneliness as a mediator of the relationship of social cognitive variables with depressive symptoms and quality of life in lung cancer patients beginning treatment.

Hyland KA, Small BJ, Gray JE, Chiappori A, Creelan BC, Tanvetyanon T, Nelson AM, Cessna-Palas J, Jim HSL, Jacobsen PB.

Psychooncology. 2019 Jun;28(6):1234-1242. doi: 10.1002/pon.5072. Epub 2019 May 3.

PMID:
30932275
25.

Impact of Stomatal Density and Morphology on Water-Use Efficiency in a Changing World.

Bertolino LT, Caine RS, Gray JE.

Front Plant Sci. 2019 Mar 6;10:225. doi: 10.3389/fpls.2019.00225. eCollection 2019. Review.

26.

Targeting Trop-2 in solid tumors: future prospects.

Zaman S, Jadid H, Denson AC, Gray JE.

Onco Targets Ther. 2019 Mar 1;12:1781-1790. doi: 10.2147/OTT.S162447. eCollection 2019. Review.

27.

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.

Creelan BC, Gray JE, Tanvetyanon T, Chiappori AA, Yoshida T, Schell MJ, Antonia SJ, Haura EB.

Br J Cancer. 2019 Apr;120(8):791-796. doi: 10.1038/s41416-019-0428-3. Epub 2019 Mar 18.

28.

Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.

Tunali I, Gray JE, Qi J, Abdalah M, Jeong DK, Guvenis A, Gillies RJ, Schabath MB.

Lung Cancer. 2019 Mar;129:75-79. doi: 10.1016/j.lungcan.2019.01.010. Epub 2019 Jan 23.

29.

Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.

Planchard D, Boyer MJ, Lee JS, Dechaphunkul A, Cheema PK, Takahashi T, Gray JE, Tiseo M, Ramalingam SS, Todd A, McKeown A, Rukazenkov Y, Ohe Y.

Clin Cancer Res. 2019 Apr 1;25(7):2058-2063. doi: 10.1158/1078-0432.CCR-18-3325. Epub 2019 Jan 18.

30.

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

Chiappori AA, Williams CC, Gray JE, Tanvetyanon T, Haura EB, Creelan BC, Thapa R, Chen DT, Simon GR, Bepler G, Gabrilovich DI, Antonia SJ.

Cancer Immunol Immunother. 2019 Mar;68(3):517-527. doi: 10.1007/s00262-018-2287-9. Epub 2018 Dec 27.

31.

Clinical associations of mucin 1 in human lung cancer and precancerous lesions.

Saltos A, Khalil F, Smith M, Li J, Schell M, Antonia SJ, Gray JE.

Oncotarget. 2018 Nov 2;9(86):35666-35675. doi: 10.18632/oncotarget.26278. eCollection 2018 Nov 2.

32.

Variability in antimicrobial use in pediatric ventilator-associated events.

Karandikar MV, Coffin SE, Priebe GP, Sandora TJ, Logan LK, Larsen GY, Toltzis P, Gray JE, Klompas M, Sammons JS, Harper MB, Horan K, Lakoma M, Cocoros NM, Lee GM.

Infect Control Hosp Epidemiol. 2019 Jan;40(1):32-39. doi: 10.1017/ice.2018.264. Epub 2018 Nov 9.

PMID:
30409233
33.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.

PMID:
30280658
34.

Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.

Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, Hicks JK, Lovinger KL, Roarty E, Rinsurongkawong W, Tang M, Sun H, Elamin Y, Lacerda LC, Lewis J, Roth JA, Swisher SG, Lee JJ, William WN Jr, Glisson BS, Zhang J, Papadimitrakopoulou VA, Gray JE, Heymach JV.

Clin Cancer Res. 2018 Dec 15;24(24):6195-6203. doi: 10.1158/1078-0432.CCR-18-1542. Epub 2018 Sep 18.

35.

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.

Gray JE, Chiappori A, Williams CC, Tanvetyanon T, Haura EB, Creelan BC, Kim J, Boyle TA, Pinder-Schenck M, Khalil F, Altiok S, Devane R, Noyes D, Mediavilla-Varela M, Smilee R, Hopewell EL, Kelley L, Antonia SJ.

Cancer Immunol Immunother. 2018 Dec;67(12):1853-1862. doi: 10.1007/s00262-018-2236-7. Epub 2018 Sep 12.

36.

Models and Mechanisms of Stomatal Mechanics.

Woolfenden HC, Baillie AL, Gray JE, Hobbs JK, Morris RJ, Fleming AJ.

Trends Plant Sci. 2018 Sep;23(9):822-832. doi: 10.1016/j.tplants.2018.06.003. Epub 2018 Jun 28. Review.

PMID:
30149855
37.

Distinct branches of the N-end rule pathway modulate the plant immune response.

Vicente J, Mendiondo GM, Pauwels J, Pastor V, Izquierdo Y, Naumann C, Movahedi M, Rooney D, Gibbs DJ, Smart K, Bachmair A, Gray JE, Dissmeyer N, Castresana C, Ray RV, Gevaert K, Holdsworth MJ.

New Phytol. 2019 Jan;221(2):988-1000. doi: 10.1111/nph.15387. Epub 2018 Aug 17.

38.

A reality check for climate change experiments: Do they reflect the real world?

Knapp AK, Carroll CJW, Griffin-Nolan RJ, Slette IJ, Chaves FA, Baur LE, Felton AJ, Gray JE, Hoffman AM, Lemoine NP, Mao W, Post AK, Smith MD.

Ecology. 2018 Oct;99(10):2145-2151. doi: 10.1002/ecy.2474. Epub 2018 Sep 4.

PMID:
30054917
39.

Rice with reduced stomatal density conserves water and has improved drought tolerance under future climate conditions.

Caine RS, Yin X, Sloan J, Harrison EL, Mohammed U, Fulton T, Biswal AK, Dionora J, Chater CC, Coe RA, Bandyopadhyay A, Murchie EH, Swarup R, Quick WP, Gray JE.

New Phytol. 2019 Jan;221(1):371-384. doi: 10.1111/nph.15344. Epub 2018 Jul 24.

40.

Midwifery pre-registration education and mid-career workforce participation and experiences.

Sheehy A, Smith RM, Gray JE, Homer CSE.

Women Birth. 2019 Apr;32(2):e182-e188. doi: 10.1016/j.wombi.2018.06.014. Epub 2018 Jul 2.

PMID:
30042066
41.

Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.

Puri S, Shafique M, Gray JE.

Curr Treat Options Oncol. 2018 Jun 21;19(8):39. doi: 10.1007/s11864-018-0556-7. Review.

PMID:
29931587
42.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.

N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.

43.

Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.

Niyongere S, Saltos A, Gray JE.

J Thorac Dis. 2018 Feb;10(Suppl 3):S433-S450. doi: 10.21037/jtd.2017.12.120. Review.

44.

Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.

Puri S, Hyland KA, Weiss KC, Bell GC, Gray JE, Kim R, Lin HY, Hoogland AI, Gonzalez BD, Nelson AM, Kinney AY, Fischer SM, Li D, Jacobsen PB, McLeod HL, Jim HSL.

Support Care Cancer. 2018 Aug;26(8):2911-2918. doi: 10.1007/s00520-018-4120-6. Epub 2018 Mar 15.

45.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
46.

Molecular control of stomatal development.

Zoulias N, Harrison EL, Casson SA, Gray JE.

Biochem J. 2018 Jan 31;475(2):441-454. doi: 10.1042/BCJ20170413. Review.

47.

The BIG protein distinguishes the process of CO2 -induced stomatal closure from the inhibition of stomatal opening by CO2.

He J, Zhang RX, Peng K, Tagliavia C, Li S, Xue S, Liu A, Hu H, Zhang J, Hubbard KE, Held K, McAinsh MR, Gray JE, Kudla J, Schroeder JI, Liang YK, Hetherington AM.

New Phytol. 2018 Apr;218(1):232-241. doi: 10.1111/nph.14957. Epub 2018 Jan 2.

48.

Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program.

Quinn GP, Pentz RD, Muñoz-Antonia T, Boyle TA, Schabath MB, Pratt CL, Shaffer A, Duarte LF, Bowman-Curci M, Antonia SJ, Chiappori AA, Creelan BC, Gray JE, Williams CC, Haura EB.

Patient Educ Couns. 2018 Apr;101(4):703-710. doi: 10.1016/j.pec.2017.11.014. Epub 2017 Nov 28.

49.

A Bayesian pick-the-winner design in a randomized phase II clinical trial.

Chen DT, Huang PY, Lin HY, Chiappori AA, Gabrilovich DI, Haura EB, Antonia SJ, Gray JE.

Oncotarget. 2017 Jul 7;8(51):88376-88385. doi: 10.18632/oncotarget.19088. eCollection 2017 Oct 24.

50.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

Supplemental Content

Support Center